Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
The purpose of this study is to evaluate the safety and effectiveness of targeted
 immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL
 or Richter's Transformation.
Inclusion Criteria:

 -  Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation

 -  Refractory to or relapsed after at least 1 prior treatment regimen

 -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

 Exclusion Criteria:

 -  Any major surgery, chemotherapy or immunotherapy within the last 14 days

 -  Known hepatitis B virus, hepatitis C virus or HIV infection

 -  Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)